PUBLISHER: TechNavio | PRODUCT CODE: 2030799
PUBLISHER: TechNavio | PRODUCT CODE: 2030799
Global Cell Therapy Market 2026-2030
The global cell therapy market is forecasted to grow by USD 18168 mn during 2025-2030, accelerating at a CAGR of 21.9% during the forecast period. The report on the global cell therapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of chronic and degenerative diseases, technological advancements and innovations in cell engineering, expanding clinical pipeline and strategic industry collaborations.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope | |
|---|---|
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 19% |
| CAGR | 21.9% |
| Incremental Value | $18168 mn |
Technavio's global cell therapy market is segmented as below:
By Type
- Autologous
- Allogenic
By Application
- Malignancies
- Musculoskeletal
- Cardiovascular
- Others
By End-User
- Biopharmaceutical companies
- CMOs
- CROs
- Academic and research institutes
Geography
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the growing emphasis on allogenic and off-shelf therapies as one of the prime reasons driving the global cell therapy market growth during the next few years. Also, strategic pivot towards solid tumor applications and integration of automation and digital technologies in manufacturing will lead to sizable demand in the market.
The report on the global cell therapy market covers the following areas:
- Global cell therapy market sizing
- Global cell therapy market forecast
- Global cell therapy market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global cell therapy market vendors that include AbelZeta Pharma Inc., Astellas Pharma Inc., Athersys Inc., Avita Medical Inc., Bayer AG, Bristol Myers Squibb Co., Castle Creek Biosciences Inc., Celyad Oncology SA, CRISPR Therapeutics AG, Gilead Sciences Inc., Johnson and Johnson Services, Kite Pharma Inc., Lineage Cell Therapeutics Inc., Novartis AG, Pharmicell Co. Ltd., Sanpower Group Co. Ltd., Sarepta Therapeutics Inc., Vericel Corp., Vertex Pharmaceuticals Inc.. Also, the global cell therapy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by Application
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- Market segments
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Cell Therapy Market 2020 - 2024
- Historic Market Size - Data Table on Global Cell Therapy Market 2020 - 2024 ($ million)
- 5.2 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
- 5.3 Application segment analysis 2020 - 2024
- Historic Market Size - Application Segment 2020 - 2024 ($ million)
- 5.4 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- 5.5 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.6 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on global cell therapy market
- 6.2 Impact of geopolitical conflicts on global cell therapy market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Type
- 8.1 Market segments
- 8.2 Comparison by Type
- 8.3 Autologous - Market size and forecast 2025-2030
- 8.4 Allogenic - Market size and forecast 2025-2030
- 8.5 Market opportunity by Type
- Market opportunity by Type ($ million)
9 Market Segmentation by Application
- 9.1 Market segments
- 9.2 Comparison by Application
- 9.3 Malignancies - Market size and forecast 2025-2030
- 9.4 Musculoskeletal - Market size and forecast 2025-2030
- 9.5 Cardiovascular - Market size and forecast 2025-2030
- 9.6 Others - Market size and forecast 2025-2030
- 9.7 Market opportunity by Application
- Market opportunity by Application ($ million)
10 Market Segmentation by End-user
- 10.1 Market segments
- 10.2 Comparison by End-user
- 10.3 Biopharmaceutical companies - Market size and forecast 2025-2030
- 10.4 CMOs - Market size and forecast 2025-2030
- 10.5 CROs - Market size and forecast 2025-2030
- 10.6 Academic and research institutes - Market size and forecast 2025-2030
- 10.7 Market opportunity by End-user
- Market opportunity by End-user ($ million)
11 Customer Landscape
- 11.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
12 Geographic Landscape
- 12.1 Geographic segmentation
- 12.2 Geographic comparison
- 12.3 North America - Market size and forecast 2025-2030
- 12.3.1 US - Market size and forecast 2025-2030
- 12.3.2 Canada - Market size and forecast 2025-2030
- 12.3.3 Mexico - Market size and forecast 2025-2030
- 12.4 Europe - Market size and forecast 2025-2030
- 12.4.1 Germany - Market size and forecast 2025-2030
- 12.4.2 UK - Market size and forecast 2025-2030
- 12.4.3 France - Market size and forecast 2025-2030
- 12.4.4 Italy - Market size and forecast 2025-2030
- 12.4.5 Spain - Market size and forecast 2025-2030
- 12.4.6 The Netherlands - Market size and forecast 2025-2030
- 12.5 Asia - Market size and forecast 2025-2030
- 12.5.1 China - Market size and forecast 2025-2030
- 12.5.2 India - Market size and forecast 2025-2030
- 12.5.3 Japan - Market size and forecast 2025-2030
- 12.5.4 South Korea - Market size and forecast 2025-2030
- 12.5.5 Indonesia - Market size and forecast 2025-2030
- 12.5.6 Thailand - Market size and forecast 2025-2030
- 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 12.6.1 Brazil - Market size and forecast 2025-2030
- 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 12.6.3 UAE - Market size and forecast 2025-2030
- 12.6.4 Turkey - Market size and forecast 2025-2030
- 12.6.5 Argentina - Market size and forecast 2025-2030
- 12.6.6 Colombia - Market size and forecast 2025-2030
- 12.6.7 South Africa - Market size and forecast 2025-2030
- 12.6.8 Israel - Market size and forecast 2025-2030
- 12.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
13 Drivers, Challenges, and Opportunity
- 13.1 Market drivers
- Increasing prevalence of chronic and degenerative diseases
- Technological advancements and innovations in cell engineering
- Expanding clinical pipeline and strategic industry collaborations
- 13.2 Market challenges
- Prohibitive costs and complex reimbursement frameworks
- Intricate distribution and supply chain logistics
- Evolving and divergent regulatory landscapes
- 13.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 13.4 Market opportunities
- Growing emphasis on allogenic and off-shelf therapies
- Strategic pivot towards solid tumor applications
- Integration of automation and digital technologies in manufacturing
14 Competitive Landscape
- 14.1 Overview
- 14.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 14.3 Landscape disruption
- Overview on factors of disruption
- 14.4 Industry risks
- Impact of key risks on business
15 Competitive Analysis
- 15.1 Companies profiled
- Companies covered
- 15.2 Company ranking index
- Company ranking index
- 15.3 Market positioning of companies
- Matrix on companies position and classification
- 15.4 AbelZeta Pharma Inc.
- AbelZeta Pharma Inc. - Overview
- AbelZeta Pharma Inc. - Product / Service
- AbelZeta Pharma Inc. - Key offerings
- SWOT
- 15.5 Astellas Pharma Inc.
- Astellas Pharma Inc. - Overview
- Astellas Pharma Inc. - Product / Service
- Astellas Pharma Inc. - Key news
- Astellas Pharma Inc. - Key offerings
- SWOT
- 15.6 Avita Medical Inc.
- Avita Medical Inc. - Overview
- Avita Medical Inc. - Product / Service
- Avita Medical Inc. - Key offerings
- SWOT
- 15.7 Bayer AG
- Bayer AG - Overview
- Bayer AG - Business segments
- Bayer AG - Key offerings
- Bayer AG - Segment focus
- SWOT
- 15.8 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
- SWOT
- 15.9 Castle Creek Biosciences Inc.
- Castle Creek Biosciences Inc. - Overview
- Castle Creek Biosciences Inc. - Product / Service
- Castle Creek Biosciences Inc. - Key offerings
- SWOT
- 15.10 Celyad Oncology SA
- Celyad Oncology SA - Overview
- Celyad Oncology SA - Product / Service
- Celyad Oncology SA - Key offerings
- SWOT
- 15.11 Gilead Sciences Inc.
- Gilead Sciences Inc. - Overview
- Gilead Sciences Inc. - Business segments
- Gilead Sciences Inc. - Key offerings
- Gilead Sciences Inc. - Segment focus
- SWOT
- 15.12 Johnson and Johnson Services
- Johnson and Johnson Services - Overview
- Johnson and Johnson Services - Business segments
- Johnson and Johnson Services - Key news
- Johnson and Johnson Services - Key offerings
- Johnson and Johnson Services - Segment focus
- SWOT
- 15.13 Kite Pharma Inc.
- Kite Pharma Inc. - Overview
- Kite Pharma Inc. - Product / Service
- Kite Pharma Inc. - Key offerings
- SWOT
- 15.14 Novartis AG
- Novartis AG - Overview
- Novartis AG - Business segments
- Novartis AG - Key news
- Novartis AG - Key offerings
- Novartis AG - Segment focus
- SWOT
- 15.15 Sanpower Group Co. Ltd.
- Sanpower Group Co. Ltd. - Overview
- Sanpower Group Co. Ltd. - Product / Service
- Sanpower Group Co. Ltd. - Key offerings
- SWOT
- 15.16 Sarepta Therapeutics Inc.
- Sarepta Therapeutics Inc. - Overview
- Sarepta Therapeutics Inc. - Product / Service
- Sarepta Therapeutics Inc. - Key offerings
- SWOT
- 15.17 Vericel Corp.
- Vericel Corp. - Overview
- Vericel Corp. - Product / Service
- Vericel Corp. - Key offerings
- SWOT
- 15.18 Vertex Pharmaceuticals Inc.
- Vertex Pharmaceuticals Inc. - Overview
- Vertex Pharmaceuticals Inc. - Product / Service
- Vertex Pharmaceuticals Inc. - Key offerings
- SWOT
16 Appendix
- 16.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 16.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 16.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 16.4 Research methodology
- Research methodology
- 16.5 Data procurement
- Information sources
- 16.6 Data validation
- Data validation
- 16.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 16.8 Data synthesis
- Data synthesis
- 16.9 360 degree market analysis
- 360 degree market analysis
- 16.10 List of abbreviations
- List of abbreviations
